Activating Brown Adipose Tissue for Weight Loss and Lowering of Blood Glucose Levels: A MicroPET Study Using Obese and Diabetic Model Mice

Chenxi Wu1, Wuying Cheng1*, Yi Sun1, Yonghong Dang1, Fengying Gong2, Huijuan Zhu2, Naishi Li2, Fang Li1, Zhaohui Zhu1*

1. Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China, 2. Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

*cwypumch@126.com (WC); zhuzhh@pumch.cn (ZZ)

Abstract

Purpose: This study aims at using 18F-FDG microPET to monitor the brown adipose tissue (BAT) glucose metabolism in obese and diabetic mouse models under different interventions, and study the therapeutic potential of BAT activation for weight loss and lowering of blood glucose in these models.

Methods: Obese mice were established by a high-fat diet for eight weeks, and diabetes mellitus (DM) models were induced with Streptozocin in obese mice. 18F-FDG microPET was used to monitor BAT function during obese and DM modeling, and also after BRL37344 (a β3-adrenergic receptor agonist) or levothyroxine treatment. The BAT function was correlated with the body weight and blood glucose levels.

Results: Compared with the controls, the obese mice and DM mice showed successively lower 18F-FDG uptake in the interscapular BAT (P = 0.036 and <0.001, respectively). After two-week BRL37344 treatment, the BAT uptake was significantly elevated in both obese mice (P = 0.010) and DM mice (P = 0.004), accompanied with significantly decreased blood glucose levels (P = 0.023 and 0.036, respectively). The BAT uptake was negatively correlated with the blood glucose levels in both obese mice (r = -0.71, P = 0.003) and DM mice (r = -0.74, P = 0.010). BRL37344 treatment also caused significant weight loss in the obese mice (P = 0.001). Levothyroxine treatment increased the BAT uptake in the control mice (P = 0.025) and obese mice (P = 0.013), but not in the DM mice (P = 0.45).

Conclusion: The inhibited BAT function in obese and DM mice can be re-activated by β3-adrenergic receptor agonist or thyroid hormone, and effective BAT activation...
may lead to weight loss and blood glucose lowering. Activating BAT can provide a new treatment strategy for obesity and DM.

Introduction

Active brown adipose tissue (BAT) has been found in adult humans, which is believed to play an important role in metabolic balance in the body [1, 2]. As demonstrated by 18F-FDG PET/CT, BAT is usually distributed symmetrically at the cervical-supraclavicular, paravertebral, and periadrenal regions. In some special circumstances, such as in patients with malignant pheochromocytoma [3], the BAT tissues in omental and mesenteric regions can also be significantly activated by cold exposure [4]. When the BATs are activated, the catecholamine released from sympathetic nerve endings will trigger the β3-adrenergic receptors and lead to high-level expression of uncoupling protein-1 (UCP1) on the inner membrane of mitochondria, which can burn glucose and fatty acids to produce heat through a process known as non-shivering thermogenesis [5]. Recently, BAT has been emerging as a promising target to treat obesity and diabetes mellitus (DM) through this special energy expenditure pathway [6–8], specifically by means of consuming fat in obese patients and lowering glucose level in DM patients [9]. Some human studies have suggested that obesity might be associated with a decreased volume of BAT [10], and mice studies have also shown that absence of BAT activity could aggravate obesity [11, 12]. Blood glucose level has been found to be interrelated with BAT activity, and the “detectable” BAT on 18F-FDG PET may serve as a protective factor against DM [13]. Although several related pre-clinical studies have been reported [8, 14, 15], most of these studies are based on in vitro biochemical analysis or pathological analysis on BAT, and themetabolic changes of BAT were not monitored in vivo. Therefore, the dynamic relationship among BAT metabolism, obesity and DM in vivo still warrants further investigation [16].

In our prior study, we tested different interventions in stimulation or inhibition of the glucose metabolism in mice BAT using 18F-FDG microPET, and have established a standardized method to evaluate BAT function [17]. In this presented study with the goal of investigating the role of BAT in disease progression and its therapeutic value, we monitored BAT function in obese and DM model mice using 18F-FDG microPET. We also evaluated BAT function change under various interventions in model mice, including BRL37344 (a specific β3-adrenergic receptor agonist) and levothyroxine (a thyroid hormone), both of which own the ability of activating the BAT metabolism [18, 19]. With these observations, we examined the feasibility of 18F-FDG microPET imaging of BAT in DM and obesity disease models, and discovered a significant relationship between BAT function, blood glucose level and body weight change. These results suggested 18F-FDG PET can provide a broad research platform for potential therapy investigations for DM...
and obesity, and also, increasing BAT metabolism can be a possible therapeutic method for DM and obesity.

Materials and Methods

Animal modeling

All animal experiments were performed under the approval of the Committee of Animal Experimentation of Peking Union Medical College Hospital (PUMCH). The mice were raised in a specific pathogen-free area with a constant room temperature of 20–21°C and a standardized light/dark cycle. All mice had ad libitum access to food and water. Five-week-old male Imprinting Control Region (ICR) mice were used in this study. Control mice were fed on basic rodent feed (barley flour 20%, soybean powder 20%, wheat bran 16%, corn flour 16%, vegetables powder 10%, fish meal 10%, bone powder 5%, salt 2%, and yeast powder 1%). Obese mice models were established by feeding a high-fat diet (70% of basic rodent feed, whole milk powder 10%, fat 10%, egg yolk powder 10%, and 10 drops of fish liver oil per kilogram diet, provided by Fukang Biotech. Co., Beijing, China) for eight weeks, and the mice with weight 20% higher than normal controls were selected as obese mice. DM model was induced on the obese mice by injecting Streptozocin (Sigma Aldrich Inc., St. Louis, MO, USA) at 160 mg/kg for consecutive three days. Mice with a fasting blood glucose level >11.1 mmol/L after Streptozocin interventions were selected as DM models.

Interventions

To activate the BAT, eight obese mice, six DM mice, and six control mice received intraperitoneal injection of BRL37344 (4-[[2-hydroxy-[3-chlorophenyl] ethyl]-amino] propyl) phenoxyacetate, Sigma Aldrich Inc., St. Louis, MO, USA) at 2.5 mg/kg three times per week for two weeks, whereas six obese mice, five DM mice, and six control mice received levothyroxine (Euthyrox, Merck KGaA, Germany) intervention at 30 μg/kg via intragastric administration three times per week for two weeks (Table 1). A total of nine normal mice that received no treatment were served as controls. The obese and DM mice were maintained on the high-fat diet during the whole experiment.

\(^{18}\)F-FDG microPET imaging and analysis

\(^{18}\)F-FDG was synthesized automatically using an FDG-N module (PET Co., Beijing, China) according to clinical requirements. The synthesis procedure had been approved by the Radiopharmaceutical Administration and complied with good-manufacturing-practice guidelines. \(^{18}\)F-FDG was pyrogen free and was of sufficient quality for clinical use, with a radiochemical purity of >98%.

A Siemens Inveon microPET imaging system was used for PET scanning of mice. A 5-min static PET acquisition was performed 1 hour after \(^{18}\)F-FDG injection for each mouse. For mice that received the BRL37344 intervention, PET
imaging was performed three times during the study at baseline, after establishment of obesity/DM model, and after BRL37344 treatment. For mice that underwent the levothyroxine intervention, a PET scan was performed after the treatment. All mice were fasted overnight before PET scanning. On the day of each PET study, all mice were pre-exposed to cold stimulation by stepping on ice (wrapped with plastic gloves and covered by utility wipes) for 1 h at room temperature before 18F-FDG injection. 18F-FDG (7.4 MBq) was injected intraperitoneally 1 h before PET scanning. Mice were under isoflurane anesthesia throughout the PET acquisition procedure. The image data were reconstructed using a Filtered Back Projection (FBP) algorithm. Semi-quantitative analysis was performed using the Siemens Inveon Research Workplace software. The maximum uptake value (nCi/cc) of 18F-FDG in the interscapular BAT and the mean uptake value in the liver were measured by volume-of-interest (VOI) method. The 18F-FDG uptake ratio of BAT to liver (BAT/L) was then calculated and compared between the groups.

**Ex vivo** biodistribution analysis

Biodistribution studies were performed in 5-week-old male ICR mice (n=12), to observe the distribution of 18F-FDG in BAT and some organs with or without interventions. Six mice received an intraperitoneal injection of BRL37344 (2.5 mg/kg) 1 h before injection of 3.7 MBq (100 μCi) 18F-FDG, whereas the six control mice received saline 1 h before 18F-FDG tracer injection. The mice were kept at room temperature after intervention and tracer injection. Immediately after the PET imaging, all mice were sacrificed and the interscapular BAT, liver, brain, muscle, and mesenteric white adipose tissue (mWAT) were isolated and weighed. Tissue radioactivity was counted using a gamma counter. The

| Groups                                    | Mouse number |
|-------------------------------------------|--------------|
| **Obesity model**                         |              |
| BRL37344 treatment                        | 8            |
| Levothyroxine treatment                   | 6            |
| Saline                                    | 8            |
| **Diabetes mellitus model: BRL37344 study**|              |
| BRL37344 treatment                        | 6            |
| Saline                                    | 5            |
| **Diabetes mellitus model: thyroxine study**|              |
| Levothyroxine treatment                   | 5            |
| Saline                                    | 6            |
| **Normal mice**                           |              |
| Single BRL37344 treatment                 | 6            |
| Levothyroxine treatment                   | 6            |
| Saline                                    | 9            |

Table 1. Groups of mice used in the studies.

doi:10.1371/journal.pone.0113742.t001
radioactive counts per min per gram tissue (CPM/g) were measured and compared between the two groups.

Blood tests
Blood tests were performed in treated mice and controls at the end of the study. All mice were fasted overnight before blood collection. For each mouse, 150–200 µL blood was collected from the retrobulbar venous plexus using a heparin pre-soaked capillary glass tube. Mice were under anesthesia for the whole blood collection process. The serum was separated through centrifugation (3500 rpm for 10 min at room temperature) and tested for blood glucose (Glu), total cholesterol (TC), and low-density lipoprotein-cholesterol (LDL-C) in the Laboratory Department in PUMCH.

Body weight monitoring
Body weight of the obese mice was monitored at baseline, after induction of obesity, and after BRL37344 treatment. Body weight of the obese mice after levothyroxine treatment was not monitored.

Statistical analysis
All data are presented as mean ± SD. SPSS statistics 17.0 software was used for statistical analysis. For two separate groups, the Student’s t-test (two-tailed, unpaired) was performed, and multiple groups were compared using analysis of variance. Correlation analysis was performed using a bivariate correlation analysis. A P value less than 0.05 was considered statistically significant.

Results
BAT glucose metabolism in obese and DM model mice
Baseline PET imaging showed no significant difference in the interscapular BAT/L uptake ratio between the groups of obese mice, DM mice, and control mice prior to any treatments. After induction of obesity and DM, the BAT uptake ratio (BAT/L) was successively decreased in the obese mice (3.15 ± 1.67, P = 0.036) and DM mice (1.97 ± 0.68, P < 0.001) compared with the controls (5.33 ± 1.48) (Fig. 1A, 1B).

Two-week BRL37344 intervention significantly increased the BAT/L in both obese mice (6.64 ± 1.97) and DM mice (5.25 ± 1.50) compared with the corresponding controls without BRL37344 treatment (4.20 ± 1.13 in obese control mice, P = 0.010; 2.32 ± 1.01 in DM control mice, P = 0.004) (Fig. 1C). In the normal control mice, single-dose BRL37344 intervention also significantly increased BAT/L compared with the untreated controls (31.74 ± 21.39 versus 7.61 ± 1.44, P = 0.002) (Fig. 1D).
BAT glucose metabolism after BRL intervention

**Ex vivo biodistribution after single-dose BRL intervention**

The 1 hour biodistribution of $^{18}$F-FDG in BAT and other tissues showed a similar pattern to that demonstrated by the microPET imaging. Single-dose BRL37344 significantly increased $^{18}$F-FDG uptake in the BAT in the normal mice (Table 2). There was no significant difference between the $^{18}$F-FDG uptake of the liver in two groups, indicating that $^{18}$F-FDG uptake in the liver was relatively stable, and the uptake ratio of BAT to liver (BAT/L) is a reliable parameter to evaluate the BAT function. The liver $^{18}$F-FDG uptake (nCi/cc) in different groups of mice did not show significant difference ($F=0.802$, $P=0.558$).
After two weeks of BRL37344 intervention, both obese and DM mice showed a significantly lower level of fasting serum glucose levels. However, the serum TC and LDL-C levels were similar to those in the obese and DM controls (Table 3). After BRL37344 treatment, the fasting serum glucose levels in both obese and DM mice showed a significant negative correlation with the BAT/L ratios ($r = -0.71$, $P = 0.003$ and $r = -0.74$, $P = 0.010$, respectively). However, no correlation was found between the TC or LDL-C levels and BAT/L in either group.

**BAT function and body weight**

After eight weeks of a high-fat diet, the weight of the obese mice was significantly increased compared with the controls ($42.52 \pm 6.16$ g versus $58.78 \pm 7.53$ g, $P = 0.001$). Two weeks of BRL37344 treatment significantly lowered the body weight of obese mice compared with untreated obese mice ($52.52 \pm 4.22$ g versus $59.09 \pm 6.89$ g, $P = 0.001$) (Fig. 2).

**Levothyroxine intervention**

In the levothyroxine treatment group, two weeks of levothyroxine intervention significantly increased BAT/L in both normal mice (Fig. 3A) ($18.44 \pm 5.76$ versus $10.64 \pm 3.24$, $P = 0.025$) and obese mice (Fig. 3B) ($13.42 \pm 7.69$ versus $4.99 \pm 2.38$, $P = 0.013$), but not significant in the DM mice (Fig. 3C) ($4.88 \pm 3.11$ versus $3.74 \pm 1.60$, $P = 0.450$). No significant change of blood glucose level was found between any of the three groups and their corresponding controls.

**Discussion**

The heat production and energy consuming function of BAT opens a potential new window for treatment of obesity and DM. Although several related preclinical and clinical studies have been performed and reported [8, 14, 15], the role of BAT in obesity and DM remains to be clarified. In this study, we examined BAT glucose metabolism in obese and DM model mice using $^{18}$F-FDG microPET, and evaluated the dynamic metabolic changes of BAT during disease progression as well as interventions including $\beta_3$-adrenergic and thyroid hormonal treatment.
The gradual deterioration of BAT function in the development of obesity and type 2 DM have been reported \cite{10, 20}, but the exact mechanism is still unclear and needs to be explored. In the present study, we found that the obese and DM model mice showed successively worse BAT function in terms of glucose metabolism. This might be due to the differences in elevated blood glucose levels for the obese and DM model mice (Table 3), and a higher level of blood glucose may have a greater inhibitory effect on the BAT glucose metabolism \cite{21}. On this basis, long-term high blood-glucose level may down-regulate related gene transcription, including glucose transporter type 4 (GLUT4) and UCP1, which has been found to be decreased in obese and diabetic animal models \cite{22–24}. Meanwhile, thicker subcutaneous fat might also keep the body core insulated from the external cold environment, thus preventing the cold stimulation to BAT.

### Table 3. Comparison of serum levels of glucose, total cholesterol, and low-density lipoprotein-cholesterol in the control, obese, and DM mice.

|                  | Glu (mmol/L) | P  | TC (mmol/L) | P  | LDL-C (mmol/L) | P  |
|------------------|--------------|----|-------------|----|----------------|----|
| Normal control   | 4.90 ± 2.01  |    | 3.29 ± 1.09 |    | 0.16 ± 0.06    |    |
| Obesity control  | 8.47 ± 1.54  | 0.023 | 5.47 ± 1.82 | 0.915 | 0.54 ± 0.11 | 0.397 |
| Obesity + BRL37344 | 6.88 ± 0.57 | 5.55 ± 0.85 | | 0.49 ± 0.13 | 0.397 |
| DM control       | 18.18 ± 9.54 | 0.036 | 6.34 ± 1.75 | 0.873 | 0.82 ± 0.21 | 0.947 |
| DM + BRL37344    | 8.84 ± 2.86  | 6.51 ± 1.60 | | 0.82 ± 0.11 | 0.397 |

Glu: serum glucose level; TC: serum level of total cholesterol; LDL-C: low-density lipoprotein-cholesterol; DM: diabetes mellitus.

doi:10.1371/journal.pone.0113742.t003

The gradual deterioration of BAT function in the development of obesity and type 2 DM have been reported \cite{10, 20}, but the exact mechanism is still unclear and needs to be explored. In the present study, we found that the obese and DM model mice showed successively worse BAT function in terms of glucose metabolism. This might be due to the differences in elevated blood glucose levels for the obese and DM model mice (Table 3), and a higher level of blood glucose may have a greater inhibitory effect on the BAT glucose metabolism \cite{21}. On this basis, long-term high blood-glucose level may down-regulate related gene transcription, including glucose transporter type 4 (GLUT4) and UCP1, which has been found to be decreased in obese and diabetic animal models \cite{22–24}. Meanwhile, thicker subcutaneous fat might also keep the body core insulated from the external cold environment, thus preventing the cold stimulation to BAT.

![Figure 2. Comparison of the changes of body weight in the obese mice with and without BRL37344 treatment. Significant weight loss was observed after two weeks of BRL37344 treatment (* P=0.001).](https://doi.org/10.1371/journal.pone.0113742.g002)
Figure 3. Comparison of brown adipose tissue (BAT) $^{18}$F-FDG uptake in the normal, obese, and diabetes mellitus (DM) mice underwent levothyroxine treatment. A, B, and C: Typical microPET images, with the arrows showing the interscapular BAT uptake of $^{18}$F-FDG in the mice. D: Semi-quantitative analysis of BAT-to-liver uptake ratio (BAT/L) showed that after two-week levothyroxine treatment, the BAT/L in the normal and obese mice were significantly increased compared to the corresponding controls ($P<0.025$ and $0.013$, respectively), whereas the increase of BAT/L in the DM mice was not significant ($P=0.450$).

doi:10.1371/journal.pone.0113742.g003
Moreover, the sympathetic nerve dysfunction seen in DM may also further block the activation of BAT from the adrenergic pathway.

$\beta_3$-adrenergic receptor controls the process of BAT thermogenesis in rodents and also in humans [25]. The activation of $\beta_3$-adrenergic receptor stimulates specifically the expression of a mitochondrial molecule, uncoupling protein-1 (UCP1), which is involved in cold-induced nonshivering thermogenesis in BAT. Therefore, $\beta_3$-adrenergic receptor agonist is an option of interest for possible clinical translation to treat obesity and DM. Although BRL3734 has some binding affinity to $\beta_1$ (Ki value 1750 nM) and $\beta_2$-adrenergic receptors (Ki value 1120 nM), it is more commonly used as a specific $\beta_3$-adrenergic receptor agonist (Ki value 287 nM) in previous studies [26, 27]. Some pre-clinical studies have shown that $\beta_3$-adrenergic receptor agonists were effective in lowering blood glucose levels in obese and/or diabetic rodent models [28, 29]. However, they did not monitor the BAT function during the interventions.

In our study, we observed a significant inverse relationship between the BAT $^{18}$F-FDG uptake and blood glucose levels in both obese and DM mice under $\beta_3$ receptor agonists. These findings not only indicate that the “dysfunctional” BAT can be re-activated, but also support the hypothesis that BAT activation has potential therapeutic value in obesity and DM. The sensitivity of BAT to BRL37344 stimulation in obese and DM mice was much lower than that in normal mice, probably owing to a blunted sympathetic nervous response to pharmaceutical and environment stimulus under conditions of obesity and DM, which was also indicated in other studies [30–33]. Since BRL37344 may still affect muscular metabolism by its low affinity to $\beta_1$ and $\beta_2$-adrenergic receptors, the skeletal muscles might also be activated under BRL37344 intervention. However, based on our ex vivo biodistribution analysis, BRL37344 intervention showed no significant effect on muscular $^{18}$F-FDG uptake. BRL37344 only increased BAT $^{18}$F-FDG uptake, but had no effect on muscle, brain, liver and WAT uptake. Therefore, the effect of BRL37344 on muscular metabolism is not the main factor for increased energy consumption and weight loss.

Thyroid hormonal activation is another recognized pathway for BAT thermogenesis [34]. Recently, several articles have reported the effect of thyroid hormone in treating obesity [35] and the relationship between thyroid hormone level and BAT function [36]. In this study, we found that two-week levothyroxine treatment could significantly increase the BAT glucose metabolism in the normal and obese mice, but not in the DM model mice. It might therefore be assumed that BAT in the DM mice is less responsive to levothyroxine intervention than that in the normal and obese mice. This phenomenon may be due to decreased function of type 2 iodothyronine deiodinase in DM mice, which has been found to be associated with increased insulin resistance and decreased BAT thermogenesis in DM [37, 38]. Moreover, although the BAT function in the normal and obese mice was increased after levothyroxine treatment in our study, we did not find significant changes of blood glucose levels between any of the levothyroxine treatment groups and their corresponding control groups. This finding may be
explained as either an inadequate dose of levothyroxine or a weaker mechanism of the thyroid hormonal activation, which needs further investigations.

Considering that tail vessels may be deteriorated by the diabetes and DM modeling and multiple injections, we selected i.p. injection as the mode of delivery for greater consistency and repeatability in experimentation. Based on published literature and our prior study (see Fig. S1), the difference between the two injection routes on BAT 18F-FDG uptake was not significant at 1 hour after tracer administration [39].

There are some limitations in this study that we considered. First, the lack of CT coregistration decreased the accuracy of PET imaging for locating interscapular BAT in mice, especially in DM and obese mice whose BAT 18F-FDG uptake is not easily detectable. In this presented study, we used liver as a background tissue for calculating BAT uptake ratio, which was not an optimal method. However, considering that liver uptake is relatively more stable than other tissues in the body, and can represent the total 18F-FDG dose injected, we chose liver as a stable background tissue for BAT uptake comparison. This method has also been reported previously [40]. In addition, our study did not perform ex-vivo analysis of BAT thermogenesis or glucose uptake by the means of classical histological or molecular approaches, which would provide more information for qualitative comparison in our imaging results. With additional ex-vivo confirmation such as BAT UCP1 expression in different animal models and under various interventions, the PET imaging results could be related to the pathophysiology change of BAT function and thus be more convictive. In the future, more efforts are needed to explore the mechanisms linking the BAT dysfunction with the sympathetic nerve control and hormonal activation pathways, as well as the effect of treatment-induced endogenous blood glucose changes on BAT metabolism.

Conclusions
BAT function progressively deteriorates in the obese and DM model mice, but can be re-activated by the β3-adrenergic receptor agonist BRL and partly by the thyroid hormone levothyroxine. According to our findings, an effective activation of BAT function might lead to weight loss and blood glucose level lowering, and the 18F-FDG uptake in BAT is negatively correlated with blood glucose level in both obese and DM mice models, although more proof is needed to elucidate the whole mechanism during the process. Therefore, BAT dysfunction seems to be an important mechanism of obesity and DM, and re-activation of BAT function can be a potential strategy for the treatment of obesity and DM.

Supporting Information
Figure S1. Comparison of BAT 18F-FDG uptake between i.v. injection and i.p. injection. The BAT 18F-FDG uptake was comparable at 30–120 minutes after
injection between the two methods, and no significant difference was found at 60 minutes after the tracer injection (\(P=0.63, n=6\) in each group).

doi:10.1371/journal.pone.0113742.S001 (TIF)

Acknowledgments

We want to thank Nan Hu, Tong Wang and Chao Ren for radiosynthesis assistance for this work. We also want to thank Don Ho for preparation of this paper.

Author Contributions

Dr. Wuying Cheng and Dr. Zhaohui Zhu are co-corresponding authors. Conceived and designed the experiments: WYC ZHZ. Performed the experiments: CXW YS WYC. Analyzed the data: CXW WYC NSL. Contributed reagents/materials/analysis tools: YHD FYG HJZ FL. Wrote the paper: CXW WYC ZHZ.

References

1. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, et al. (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360: 1509–1517.

2. Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T, et al. (2009) High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 58: 1526–1531.

3. Cheng W, Zhu Z, Jin X, Chen L, Zhuang H, et al. (2012) Intense FDG activity in the brown adipose tissue in omental and mesenteric regions in a patient with malignant pheochromocytoma. Clin Nucl Med 37: 514–515.

4. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, et al. (2011) Brown adipose tissue activity controls triglyceride clearance. Nat Med 17: 200–205.

5. Heaton GM, Wagenvoord RJ, Kemp A Jr, Nicholls DG (1978) Brown-adipose-tissue mitochondria: photoaffinity labelling of the regulatory site of energy dissipation. Eur J Biochem 82: 515–521.

6. Cypess AM, Kahn CR (2010) Brown fat as a therapy for obesity and diabetes. Curr Opin Endocrinol Diabetes Obes 17: 143–149.

7. Seale P, Lazar MA (2009) Brown fat in humans: turning up the heat on obesity. Diabetes 58: 1482–1484.

8. Sacks H, Symonds ME (2013) Anatomical locations of human brown adipose tissue: functional relevance and implications in obesity and type 2 diabetes. Diabetes 62: 1783–1790.

9. Nedergaard J, Cannon B (2010) The changed metabolic world with human brown adipose tissue: therapeutic visions. Cell Metab 11: 268–272.

10. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, et al. (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360: 1500–1508.

11. Feldmann HM, Golozoubova V, Cannon B, Nedergaard J (2009) UCP1 ablation induces obesity and abolishes diet-induced thermogenesis in mice exempt from thermal stress by living at thermoneutrality. Cell Metab 9: 203–209.

12. Kontani Y, Wang Y, Kimura K, Inokuma KI, Saito M, et al. (2005) UCP1 deficiency increases susceptibility to diet-induced obesity with age. Aging Cell 4: 147–155.

13. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, et al. (2000) Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105: 271–278.
14. Vosselman MJ, van Marken Lichtenbelt WD, Schrauwen P (2013) Energy dissipation in brown adipose tissue: From mice to men. Mol Cell Endocrinol.

15. Vijgen GH, Bouvy ND, Teule GJ, Brans B, Hoeks J, et al. (2012) Increase in brown adipose tissue activity after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 97: E1229–1233.

16. Jacene HA, Cohade CC, Zhang Z, Wahl RL (2011) The relationship between patients’ serum glucose levels and metabolically active brown adipose tissue detected by PET/CT. Mol Imaging Biol 13: 1278–1293.

17. Wu C, Cheng W, Xing H, Dang Y, Li F, et al. (2011) Brown adipose tissue can be activated or inhibited within an hour before 18F-FDG injection: a preliminary study with microPET. J Biomed Biotechnol 2011: 159834.

18. Granneman JG (1990) Norepinephrine and BRL 37344 stimulate adenylate cyclase by different receptors in rat brown adipose tissue. J Pharmacol Exp Ther 254: 508–513.

19. Bianco AC, McAninch EA (2013) The role of thyroid hormone and brown adipose tissue in energy homeostasis. Lancet Diabetes Endocrinol 1: 250–258.

20. Vijgen GH, Bouvy ND, Teule GJ, Brans B, Schrauwen P, et al. (2011) Brown adipose tissue in morbidly obese subjects. PLoS One 6: e17247.

21. Williams G, Kolodny GM (2008) Method for decreasing uptake of 18F-FDG by hypermetabolic brown adipose tissue on PET. AJR Am J Roentgenol 190: 1406–1409.

22. Samuel VT, Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148: 852–871.

23. Richardson JM, Balon TW, Treadway JL, Pessin JE (1991) Differential regulation of glucose transporter activity and expression in red and white skeletal muscle. J Biol Chem 266: 12690–12694.

24. Vasiljevic A, Vojcic L, Dinulovic I, Buzadzic B, Korac A, et al. (2010) Expression pattern of thermogenesis-related factors in interscapular brown adipose tissue of alloxan-treated rats: beneficial effect of L-arginine. Nitric Oxide 23: 42–50.

25. Wijers SL, Schrauwen P, van Baak MA, Saris WH, van Marken Lichtenbelt WD (2011) Beta-adrenergic receptor blockade does not inhibit cold-induced thermogenesis in humans: possible involvement of brown adipose tissue. J Clin Endocrinol Metab 96: E598–605.

26. Nisoli E, Tonello C, Benarese M, Carruba MO (1995) Rat frontal cortex beta 1-adrenoceptors are activated by the beta 3-adrenoceptor agonists SR 58611A and SR 58878A but not by BRL 37344 or ICI 215,001. J Neurochem 65: 1580–1587.

27. Suarez J, Rivera P, Arrabal S, Crespillo A, Serrano A, et al. (2014) Oleoylthanolamide enhances beta-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis Model Mech 7: 129–141.

28. Williams CA, Shih MF, Taberner PV (1999) Sustained improvement in glucose homeostasis in lean and obese mice following chronic administration of the beta 3 agonist SR 58611A. Br J Pharmacol 128: 1586–1592.

29. Liu X, Perusse F, Bukowiecki LJ (1998) Mechanisms of the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker-ZDF rats. Am J Physiol 274: R1212–1219.

30. Masuo K, Lambert GW (2011) Relationships of adrenoceptor polymorphisms with obesity. J Obes 2011: 609485.

31. Bhadada SV, Patel BM, Mehta AA, Goyal RK (2011) beta(3) Receptors: Role in Cardiometabolic Disorders. Ther Adv Endocrinol Metab 2: 65–79.

32. Esler M, Rumantr M, Wiesner G, Kaye D, Hastings J, et al. (2001) Sympathetic nervous system and insulin resistance: from obesity to diabetes. American journal of hypertension 14: 304S–309S.

33. Straznicky NE, Eikelis N, Nestel P, Dixon JB, Dawood T, et al. (2012) Baseline sympathetic nervous system activity predicts dietary weight loss in obese metabolic syndrome subjects. J Clin Endocrinol Metab 97: 605–613.

34. Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84: 277–359.
35. Kaptein EM, Beale E, Chan LS (2009) Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review. J Clin Endocrinol Metab 94: 3663–3675.

36. Bredella MA, Fazeli PK, Freedman LM, Calder G, Lee H, et al. (2012) Young women with cold-activated brown adipose tissue have higher bone mineral density and lower Pref-1 than women without brown adipose tissue: a study in women with anorexia nervosa, women recovered from anorexia nervosa, and normal-weight women. J Clin Endocrinol Metab 97: E584–590.

37. Dora JM, Machado WE, Rheinheimer J, Crispim D, Maia AL (2010) Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and meta-analysis. Eur J Endocrinol 163: 427–434.

38. Villarroya F, Vidal-Puig A (2013) Beyond the sympathetic tone: the new brown fat activators. Cell Metab 17: 638–643.

39. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, et al. (2006) Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 47: 999–1006.

40. Drubach LA, Palmer EL 3rd, Connolly LP, Baker A, Zurakowski D, et al. (2011) Pediatric brown adipose tissue: detection, epidemiology, and differences from adults. J Pediatr 159: 939–944.